Laxatives
In clinical developmentAlso known as LAXATIVES,OTHER, Laxative.
Recent clinical, regulatory, research and industry developments relating to this drug.
Impact of commonly used drugs on the composition and metabolic function of the gut microbiota.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes1
Journals, researchers & institutions
- Nature communications1
- Bourgonje AR1
- Collij V1
- Fu J1
- Imhann F1
- Jonkers DMAE1
- Kurilshikov A1
- Masclee AAM1
- Mujagic Z1
- Maastricht University Medical Center1
- University of Groningen and University Medical Center Groningen1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across the same disease area as Laxatives in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials